AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

5. Appraisal 1: Full Submission (WPAS) Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) for the treatment of adults infected with human immunodeficiency virus 1 without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir

To protect commercial confidentiality the following appraisals will be held in private

6. Appraisal 2: Limited Submission Fosaprepitant (Ivemend®) for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy

7. Appraisal 3: Limited Submission Tiotropium (Spiriva® Respimat®) as add-on maintenance bronchodilator treatment in patients aged 6 years to <18 years with severe asthma who experienced one or more severe asthma exacerbations in the preceding year

8. Appraisal 3: Limited Submission Fosaprepitant (Ivemend®) for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy

The meeting will now open to the public for the committee decisions

Date of next meeting – Wednesday, 12th December 2018 in Cardiff